Author: Mohammadzadeh, Sara; Khabiri, Alireza; Roohvand, Farzin; Memarnejadian, Arash; Salmanian, Ali Hatef; Ajdary, Soheila; Ehsani, Parastoo
Title: Enhanced-Transient Expression of Hepatitis C Virus Core Protein in Nicotiana tabacum, a Protein With Potential Clinical Applications Document date: 2014_11_24
ID: 3posyr5n_1
Snippet: Hepatitis C virus (HCV), the major cause of blood-borne chronic hepatitis with potential progression to cirrhosis, has infected around 170 million people globally (1) . Due to heterogeneity of HCV proteins, their high mutation rates and complex pathogenesis, no approved vaccine for human application against this viral infection is available to date (2, 3) . Recognition of conserved epitopes in HCV proteins and advancements in the formulation of v.....
Document: Hepatitis C virus (HCV), the major cause of blood-borne chronic hepatitis with potential progression to cirrhosis, has infected around 170 million people globally (1) . Due to heterogeneity of HCV proteins, their high mutation rates and complex pathogenesis, no approved vaccine for human application against this viral infection is available to date (2, 3) . Recognition of conserved epitopes in HCV proteins and advancements in the formulation of vaccines in novel modalities, however, have led to the placement of a few HCV vaccines in the pipeline of human clinical trials in recent years (4, 5) . HCV holds a single-stranded positive-sense RNA genome which encodes for three structural (core protein and envelope proteins E1 and E2) and six nonstructural proteins (4) . Among the HCV proteins, core (HCVcp) is the most conserved HCV antigen, and hence, a good candidate to be considered for HCV vaccine formulations (4) (5) (6) . Accordingly, application of even isolated HCVcp-CTL epitopes (8-10 amino acids) in the context of synthetic multi-epitope HCV vaccines has also been reported (7) (8) (9) . Besides, anticore antibodies are the first to be raised after the onset of infection, a property that has provided an important diagnostic value for this protein and has located it among antibody-capturing antigens in commercially available serological assays for HCV diagnosis (10) . In addition, nucleotide sequence of HCVcp is supposed to encode for other alternated frame-shift proteins (ARFPs) with important pathogenic roles in chronic HCV infection and cirrhosis (4, 11) . Therefore, to fulfill different diagnostic, research and therapeutic demands, production of HCVcp in various expression systems has been addressed (4) (5) . However, since the C-terminal hydrophobic region of HCVcp exerts immune-suppressive effects (4, 12) , its first 120 N-terminal residues, the hydrophilic region (HCVcp N-120), which contains both nuclear localization signals (NLS) (13) and most of the conserved B and T cell epitopes, is usually employed for different diagnostic (10, 14) and vaccine applications (15) (16) (17) .
Search related documents:
Co phrase search for related documents- amino acid and chronic HCV infection: 1, 2, 3, 4, 5
- amino acid and chronic hepatitis: 1, 2, 3, 4, 5, 6, 7, 8, 9
- amino acid and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8
- amino acid and complex pathogenesis: 1
- amino acid and core protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
- amino acid and diagnostic value: 1, 2, 3
- amino acid and envelope protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- amino acid and expression system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- amino acid and frame shift: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- amino acid and good candidate: 1, 2, 3, 4, 5, 6
- amino acid and HCV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- amino acid and HCV protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- amino acid and HCV vaccine: 1, 2
- amino acid and high mutation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- amino acid and high mutation rate: 1, 2, 3, 4, 5, 6, 7, 8, 9
- amino acid and human application: 1
- amino acid and hydrophilic region: 1, 2, 3, 4, 5
- amino acid and hydrophobic region: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- amino acid and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
Co phrase search for related documents, hyperlinks ordered by date